tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Smart Growth
New
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
News
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
TipRanks Momentum Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Most Visited Websites
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Class Actions
Class Actions
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us

ARDS Stock Latest News

Aridis Pharmaceuticals continuing to explore ‘multiple paths to monetize’ assets
The FlyAridis Pharmaceuticals continuing to explore ‘multiple paths to monetize’ assets
11d ago
ARDS
Aridis Pharmaceuticals price target lowered to $2 from $10 at H.C. Wainwright
PremiumThe Fly
Aridis Pharmaceuticals price target lowered to $2 from $10 at H.C. Wainwright
1y ago
ARDS
Aridis Pharmaceuticals prices 10M shares at 20c in offering
PremiumThe Fly
Aridis Pharmaceuticals prices 10M shares at 20c in offering
1y ago
ARDS
Biotech Alert: Searches spiking for these stocks today
PremiumThe Fly
Biotech Alert: Searches spiking for these stocks today
1y ago
ADVM
ARDS
Aridis Pharmaceuticals’ AR-301 receives FDA’s QIDP designation
PremiumThe Fly
Aridis Pharmaceuticals’ AR-301 receives FDA’s QIDP designation
1y ago
ARDS
Aridis Pharmaceuticals’ AR-301 is eligible for consideration under FDA’s LPAD
PremiumThe FlyAridis Pharmaceuticals’ AR-301 is eligible for consideration under FDA’s LPAD
2y ago
ARDS
Aridis Pharmaceuticals receives Nasdaq notice on late filing of Form 10-K
Premium
The Fly
Aridis Pharmaceuticals receives Nasdaq notice on late filing of Form 10-K
2y ago
ARDS
Aridis Pharmaceuticals (ARDS) Q4 Earnings Cheat Sheet
Premium
Pre-Earnings
Aridis Pharmaceuticals (ARDS) Q4 Earnings Cheat Sheet
2y ago
ARDS
Aridis Pharmaceuticals announces $2.28M registered direct offering
PremiumThe Fly
Aridis Pharmaceuticals announces $2.28M registered direct offering
2y ago
ARDS
Aridis Skyrockets on Impressive Data In Cystic Fibrosis
PremiumMarket News
Aridis Skyrockets on Impressive Data In Cystic Fibrosis
2y ago
ARDS
Aridis meets primary, secondary endpoints in Phase 2a study of AR-501
PremiumThe Fly
Aridis meets primary, secondary endpoints in Phase 2a study of AR-501
2y ago
ARDS
Biotech Alert: Searches spiking for these stocks today
PremiumThe Fly
Biotech Alert: Searches spiking for these stocks today
2y ago
ARDS
CYTO
Aridis Pharmaceuticals price target lowered to $10 from $19 at H.C. Wainwright
PremiumThe FlyAridis Pharmaceuticals price target lowered to $10 from $19 at H.C. Wainwright
2y ago
ARDS
Aridis drops after endpoint in AR-301–002 study not statistically significant
Premium
The Fly
Aridis drops after endpoint in AR-301–002 study not statistically significant
2y ago
ARDS
Aridis: No statistical significance in primary endpoint in AR-301–002 study
Premium
The Fly
Aridis: No statistical significance in primary endpoint in AR-301–002 study
2y ago
ARDS
Aridis to present AR 501 Phase 2 trial update for CF treatment at KOL
PremiumThe Fly
Aridis to present AR 501 Phase 2 trial update for CF treatment at KOL
2y ago
ARDS
Aridis receives $4.85M investment from the Cystic Fibrosis Foundation
PremiumThe Fly
Aridis receives $4.85M investment from the Cystic Fibrosis Foundation
2y ago
ARDS
Aridis signs deal for commercial licenses for pan-Ebola, pan-Marburg programs
PremiumThe Fly
Aridis signs deal for commercial licenses for pan-Ebola, pan-Marburg programs
2y ago
ARDS
Aridis Pharmaceuticals closes patient enrollment in Phase 2a study of AR-501
PremiumThe Fly
Aridis Pharmaceuticals closes patient enrollment in Phase 2a study of AR-501
2y ago
ARDS
Here’s Why Aridis Pharmaceuticals Dropped 30%
PremiumMarket NewsHere’s Why Aridis Pharmaceuticals Dropped 30%
2y ago
ARDS

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >